Table 1. Key eligibility criteria... | American Society of Hematology

Table 1.

Key eligibility criteria

Inclusion criteria	Exclusion criteria
Studies of DLBCL that included an assessment of the impact of DI of ≥1 drug component of R-CHOP on survival outcomes	Studies with <100 patients DLBCL receiving R-CHOP-21
Most patients newly diagnosed with untreated DLBCL	Previously treated DLBCL
Inclusion of alternative histologies permitted, provided these represent a small minority of patients (e.g., transformed follicular lymphoma, PMBL)	Primary CNS lymphoma
Included ≥100 patients treated with R-CHOP-21 protocol*	No DDI
Full-text articles in the English language	No assessment of the impact of DI on survival outcome†
Retrospective studies	Case studies
Cohort studies	Review articles
Observational studies	Pharmacokinetic studies
Controlled trials that include an R-CHOP–treated arm†	Opinion papers
	Commentaries
	Editorials
	Case reports
	Conference abstracts

Inclusion criteria	Exclusion criteria
Studies of DLBCL that included an assessment of the impact of DI of ≥1 drug component of R-CHOP on survival outcomes	Studies with <100 patients DLBCL receiving R-CHOP-21
Most patients newly diagnosed with untreated DLBCL	Previously treated DLBCL
Inclusion of alternative histologies permitted, provided these represent a small minority of patients (e.g., transformed follicular lymphoma, PMBL)	Primary CNS lymphoma
Included ≥100 patients treated with R-CHOP-21 protocol*	No DDI
Full-text articles in the English language	No assessment of the impact of DI on survival outcome†
Retrospective studies	Case studies
Cohort studies	Review articles
Observational studies	Pharmacokinetic studies
Controlled trials that include an R-CHOP–treated arm†	Opinion papers
	Commentaries
	Editorials
	Case reports
	Conference abstracts

Variant regimens where doxorubicin is replaced with a derivative anthracycline were accepted.

Nonrandomized, single-arm trials with dose-attenuated R-CHOP, in which no attempt was made to examine the effect of RDI on survival outcome.